DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $113,000 | +391.3% | 3,700 | +362.5% | 0.01% | +350.0% |
| Q2 2022 | $23,000 | +360.0% | 800 | +379.0% | 0.00% | – |
| Q1 2022 | $5,000 | -97.0% | 167 | -95.5% | 0.00% | -100.0% |
| Q4 2021 | $166,000 | +690.5% | 3,742 | +768.2% | 0.01% | +550.0% |
| Q3 2021 | $21,000 | -79.4% | 431 | -67.0% | 0.00% | -75.0% |
| Q2 2021 | $102,000 | -74.9% | 1,306 | -81.7% | 0.01% | -79.5% |
| Q1 2021 | $407,000 | +284.0% | 7,129 | +139.1% | 0.04% | +225.0% |
| Q3 2020 | $106,000 | +37.7% | 2,981 | -33.4% | 0.01% | +50.0% |
| Q4 2019 | $77,000 | – | 4,477 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |